AzTrials
AzTrials

Second Primary Colorectal CancerNCT06189547

Impact of 10 Different Prior Cancer History on Survival of Patients Who Underwent Surgery for Second Primary Colorectal Cancer: a Population-based Cohort Study

An observational study of Second Primary Colorectal Cancer, run by Guangzhou Medical University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study, the investigators collected data with the SEER*Stat software version 8.4.1 (accession number: 20377-Nov2021). The patients with confirmed diagnoses of CRC (site code C18.0-20.9 and C26.0) between 2004 and 2013 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Second Primary Colorectal Cancer
What is being tested?
different prior cancer history type
How many people
82,770 participants
Where
1 siteChina
Study dates
2 Feb 2023to 12 Nov 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: We used population-based data from the 9 oldest SEER areas, which represented approximately 9% of the US population.

Who may be able to join

  • confirmed diagnoses of CRC (site code C18.0-20.9 and C26.0)
  • Diagnosis Year between 2004 and 2013

Who cannot join

  • Patients with more than one cancer in the past
  • The patient's age at diagnosis was <18 years old
  • Patients with incomplete survival data and follow-up information
  • Patients only had autopsy or death certificate records

Trial locations and contacts

1 site in 1 country.

China1 site
  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120

Other trials in China

About this study

Official title: Master's Student in Gastrointestinal Surgery at the First Affiliated Hospital of Guangzhou Medical University

In this study, the investigators collected data with the SEER*Stat software version 8.4.1 (accession number: 20377-Nov2021). The patients with confirmed diagnoses of CRC (site code C18.0-20.9 and C26.0) between 2004 and 2013 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Due to the significant disparity in the number of cancer survivors with various prior cancer types among newly diagnosed CRC patients, the investigators utilized the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) Site Recode to identify 10 common previous cancer sites, including the colorectum, prostate, breast, uterus, bladder, skin, lung, kidney, thyroid, and stomach. CRC patients with a prior history of cancer originated from one of the 10 sites and surgical CRC patients without a prior history of cancer were enrolled in this study. The exclusion criteria were as follows: (1) Patients with more than one cancer in the past; (2) The patient's age at diagnosis was <18 years old; (3) Patients with incomplete survival data and follow-up information; (4) Patients only had autopsy or death certificate records.

The primary outcomes of this study were overall survival (OS) and cancer-specific survival (CSS). OS was defined as the time from diagnosis to date of death(patients who were still alive at the end of follow-up were considered as censored data. CSS was defined as the time from diagnosis to date of death caused by CRC (patients who deaths from other causes or still alive at the end of follow-up were considered as censored data). The investigators set December 31, 2018, as the cut-off date for follow-up to ensure that all included cases (diagnosed in 2004-2013) were followed for at least 5 years.

Read more

Based on prior cancer history, the surgical cases were categorized into two groups: 'Non-prior cancer history' and 'Prior cancer history.' The 'Prior cancer history' group was further subcategorized by the type of prior cancer, including colorectum, prostate, breast, uterus, bladder, skin, lung, kidney, thyroid and stomach. The bias between different Prior cancer history group and Non-prior cancer history group was minimized by Propensity Score Matching (PSM), and the Kaplan-Meier method and log-rank tests were used to compare OS and CSS differences. And then, a multivariate Cox proportional hazards model was performed to estimate the hazard ratios (HR) and 95% confidence interval (CI) to analyze whether different types of prior cancer history impacted the OS and CSS in patients who underwent surgery for spCRC independently. Common demographic and clinicopathological data, including age at diagnosis of spCRC, sex, race, marital status, tumor location of spCRC, pathologic grade of spCRC, TNM stage of spCRC (0-I, II-III, IV and unknown) and chemotherapy status were entered as covariates. Kaplan-Meier curves were also constructed according to the time since first cancer diagnosis (latency), age diagnosed with spCRC, and spCRC stage.

Further analysis was performed to determine the impact of surgery on survival of spCRC patients with different type of prior cancer history. The investigators divided patients into surgical and non-surgical groups based on whether surgery was performed, and then assessed the effect of surgery on survival using the propensity score-adjusted Kaplan-Meier method.

In this study, the baseline characteristics of patients were compared using Chi-square test and Fisher's exact test. A one-to-one propensity score matching (PSM) was performed to reduce the selection bias of the two groups of baseline variables. When performing one-to-one propensity score matching between the prior cancer history group and the non-prior cancer history group, the investigators chose a caliper of 0.2. However, the investigators opted for different calipers when matching the surgical and non-surgical groups because the investigators believe that patients with different prior cancers were in entirely different situations. A two-sided probability value of P ≤ 0.05 was considered statistically significant. R software (version 4.2.3) was used for all statistical analysis.

Being tested
different prior cancer history type

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • different prior cancer history typeOther

    different types of prior cancer history

Study groups in NCT06189547
Study groupRoleWhat they receive
Without prior cancerNot described
With prior colorectal cancer historyNot described
Receives: Other: different prior cancer history type
With prior prostate cancer historyNot described
Receives: Other: different prior cancer history type
With prior breast cancer historyNot described
Receives: Other: different prior cancer history type
With prior uterine cancer historyNot described
Receives: Other: different prior cancer history type
With prior bladder cancer historyNot described
Receives: Other: different prior cancer history type
With prior skin cancer historyNot described
Receives: Other: different prior cancer history type
With prior lung cancer historyNot described
Receives: Other: different prior cancer history type
With prior kidney cancer historyNot described
Receives: Other: different prior cancer history type
With prior thyroid cancer historyNot described
Receives: Other: different prior cancer history type
With prior stomach cancer historyNot described
Receives: Other: different prior cancer history type

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. overall survival (OS)

    OS was defined as the time from diagnosis to date of death(patients who were still alive at the end of follow-up were considered as censored data).

    Measured: From the initial diagnosis of colorectal cancer, at the end of each month

Secondary outcomes (1)
  1. cancer-specific survival (CSS)

    CSS was defined as the time from diagnosis to date of death caused by CRC (patients who deaths from other causes or still alive at the end of follow-up were considered as censored data)

    Measured: From the initial diagnosis of colorectal cancer, at the end of each month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jan 2024
  2. Study start2 Feb 2023
  3. Primary completion10 Nov 2023
  4. Study completion12 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
82,770 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06189547
Sponsor's protocol ID
GMChen
Status last verified
Dec 2023
First submitted
9 Dec 2023
Last updated
3 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Zhou H, Huang Y, Qiu Z, Zhao H, Fang W, Yang Y, Zhao Y, Hou X, Ma Y, Hong S, Zhou T, Zhang Y, Zhang L. Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A pan-cancer analysis of the SEER database. Int J Cancer. 2018 Oct 1;143(7):1569-1577. doi: 10.1002/ijc.31543. Epub 2018 May 7.

    PubMed 29667174
  • Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409-436. doi: 10.3322/caac.21731. Epub 2022 Jun 23.

    PubMed 35736631
  • Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36. doi: 10.1158/1055-9965.EPI-16-0133.

    PubMed 27371756
  • Murphy CC, Gerber DE, Pruitt SL. Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program. JAMA Oncol. 2018 Jun 1;4(6):832-836. doi: 10.1001/jamaoncol.2017.3605.

    PubMed 29167866
  • Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014 Sep 24;106(11):dju302. doi: 10.1093/jnci/dju302. Print 2014 Nov.

    PubMed 25253615

Questions about this trial

What is this clinical trial studying?

An observational study of Second Primary Colorectal Cancer, run by Guangzhou Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

overall survival (OS) (time frame: From the initial diagnosis of colorectal cancer, at the end of each month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06189547, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in